RhumbLine Advisers’s LB Pharmaceuticals LBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.09M Buy
28,314
+525
+2% +$21.7K ﹤0.01% 2223
2026
Q2
$902K Buy
27,789
+10,686
+62% +$314K ﹤0.01% 2379
2026
Q1
$422K Buy
17,103
+820
+5% +$18.9K ﹤0.01% 2715
2025
Q4
$362K Buy
+16,283
New +$284K ﹤0.01% 2865

Other funds holding LBRX

RhumbLine Advisers's LBRX Position: Q3 2026 in Review

RhumbLine Advisers increased its LB Pharmaceuticals (LBRX) stake by 1.9% in Q3 2026, buying an estimated $21.7K and bringing the position to 28,314 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

RhumbLine Advisers first reported a position in LBRX in Q4 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

  • RhumbLine Advisers held 28,314 shares of LB Pharmaceuticals worth $1.09M as of Q3 2026.
  • RhumbLine Advisers bought 525 LB Pharmaceuticals shares in Q3 2026, an estimated $21.7K.
  • LB Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2223 holding.
  • RhumbLine Advisers first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.